HERtiCAD (trastuzumab biosimilar) / Biocad - LARVOL DELTA

Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. (PubMed, Immunopharmacol Immunotoxicol) - "The cumulative ranking curve (SUCRA) probability indicated that the ORR from best to worst was CT-P6, Herceptin, HLX02, PF-05280014, R-TPR-016, BCD-022, MYL-1401O, SB3, and the pCR from best to worst was PF-05280014, CT-P6, Herceptin, ABP-980, SB3...Both CT-P6 and PF-05280014 are better in the overall curative effect, but CT-P6 had the highest serious adverse reactions when compared with others. The PF-05280014 might be a better trastuzumab biosimilar in the treatment of HER2-positive breast cancer patients."

Journal • Retrospective data • Review • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis (SABCS 2022) - P=N/A | "METHODS High-risk BC pts (n=195) with II-III stages are getting NAC of the following regimens: 4 dose dense doxorubucin/cyclophosphamide with E followed by 12 weekly paclitaxel/carboplatin (4ddAC+E/12P+carbo) for triple negative (TN) pts or 4 dose dense doxorubucin/cyclophosphamide with E followed by 4 dose dense paclitaxel with E (4ddAC+E /4ddP+E) for HR+HER2- pts and 6 docetaxel/carboplatin trastuzumab/pertuzumab (TCHP+E) for HER2+ pts. High pCR rate under E in HER2+ BC pts focused on further confirmation with translational research. KEY WORDS: empegfilgrastim, neutropenia, pCR, dose intensity, G-CSF, breast carcinoma, neoadjuvant therapy"

Clinical • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CSF3

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. (PubMed, BMC Cancer) - P3 | "Thus, the results of this study demonstrated therapeutic equivalence of bevacizumab biosimilar BCD-021 and referent bevacizumab drug."

Journal • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. (PubMed, BMC Cancer) - P3 | "Thus, results of this study have demonstrated therapeutic equivalence of trastuzumab biosimilar BCD-022 and referent trastuzumab drug."

Clinical • Journal • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Biocad and ICM gain biosimilar foothold in Southeastern Europe (Center for Biosimilars) - "The registration for the biosimilars of rituximab and trastuzumab, Acellbia and Herticad, respectively, was granted by The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina. Market launch, largely through individual contracts with state and private cancer centers, will start this year."

European regulatory